RT Journal Article SR Electronic T1 Characterization of Mdr1a/P-glycoprotein Knockout Rats Generated by Zinc Finger Nucleases JF Molecular Pharmacology JO Mol Pharmacol FD American Society for Pharmacology and Experimental Therapeutics SP mol.111.074179 DO 10.1124/mol.111.074179 A1 Xiaoyan Chu A1 Zuo Zhang A1 Jocelyn Yabut A1 Sarah Horwitz A1 John Levorse A1 Xiang-qing Li A1 Lei Zhu A1 Harmony Lederman A1 Rachel Ortiga A1 John Strauss A1 Xiaofang Li A1 Karen A Owens A1 Jasminka Dragovic A1 Thomas F Vogt A1 Raymond Evers A1 Myung K Shin YR 2011 UL http://molpharm.aspetjournals.org/content/early/2011/11/02/mol.111.074179.abstract AB The development of the Zinc Finger Nuclease (ZFN) technology has enabled the genetic engineering of the rat genome. The ability to manipulate the rat genome has great promise to augment the utility of rats for biological and pharmacological studies. A Wistar Hannover rat model lacking the multidrug resistance protein Mdr1a P-glycoprotein (P-gp) was generated using a rat Mdr1a specific ZFN. Mdr1a was completely absent in some tissues, including brain and small intestine, of the knockout rat. Pharmacokinetic studies with the Mdr1a P-gp substrates loperamide, indinavir, and talinolol indicated that Mdr1a was functionally inactive in the blood-brain barrier and intestine in the Mdr1a-/- rats. To identify possible compensatory mechanisms in Mdr1a-/- rats, the expression level of 90 drug metabolizing enzyme and transporter related genes was compared in brain, liver, kidney and intestine of male and female Mdr1a-/- and control rats. In general, alterations in gene expression of these genes in Mdr1a-/- rats appeared to be modest, with more changes in female than in male rats. Taken together, our studies demonstrate that the ZFN generated Mdr1a-/- rat will be a valuable tool for central nervous system (CNS) drug target validation and determining the role of P-gp in drug absorption and disposition